IP Library Granted Patent US 7,749,760
Granted Patent B2
US 7,749,760 · App. 12/316,973 · Granted Jul 6, 2010

Vγ9Vδ2 T cell proliferation agent, method for producing activated Vγ9Vδ2 T cells, and uses thereof

Assignee: Hyogo College of Medicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,749,760
App. No.
12/316,973
Granted
Jul 6, 2010
Kind
B2
Abstract

A Vγ9Vδ2 T cell proliferation agent includes at least a bisphosphonate, interleukin 2, and interleukin 18. Since IL-18 has properties that improve cell viability by inhibiting cell death, IL-18 is presumably capable of acting as a cofactor for the bisphosphonate so as to significantly increase the effect of Vγ9Vδ2 T cell proliferation by the bisphosphonate and the IL-2. This allows providing a Vγ9Vδ2 T cell proliferation agent capable of growing Vγ9Vδ2 T cells with a proliferated efficiency significantly high compared to conventional methods so that the proliferated Vγ9Vδ2 T cells have a high antitumor activity and high cytokine productivity.

Claims (4)

1. A Vγ9Vδ2 T cell proliferation agent comprising at least zoledronate, interleukin 2, and interleukin 18.

2. A method for producing an activated Vγ9Vδ2 T cell, comprising:

stimulating a Vγ9Vδ2 T cell with at least zoledronate interleukin 2, and interleukin 18.

3. A Vγ9Vδ2 T cell proliferation kit comprising at least a Vγ9Vδ2 T cell, zoledronate, interleukin 2, and interleukin 18.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2008
From: OKAMURA, HARUKI; KUBO, SHUJI; LI, WEN
To: HYOGO COLLEGE OF MEDICINE
Reel/Frame 022056/0915 →
Priority Claims (1)
JP 2008-180749 · Jul 10, 2008 · national
Continuity (1)
Related Publication 20100009447A1 · Jan 14, 2010